Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study
- Author
- FALKSON, C. I; IBRAHIM, J; KIRKWOOD, J. M; CRATES, A. S; ATKINS, M. B; BLUM, R. H
Dana-Farber Cancer Institute, Tufts-New England Medical Center, Boston, MA, United States
Royal Prince Alfred Hospital, Camperdown, Australia
Saint Vincents Comprehensive Cancer Center, New York, NY, United States
University of Pittsburgh, Pittsburgh, PA, United States
University of Pretoria, Pretoria, South Africa - Source
Journal of clinical oncology. 1998, Vol 16, Num 5, pp 1743-1751 ; ref : 41 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agent alkylant Anticancéreux Antihormone Antioestrogène Association médicamenteuse Chimiothérapie Complication Composé non stéroïde Dacarbazine Efficacité traitement Essai clinique phase III Etude comparative Homme Immunothérapie Interféron alpha Mélanome Pronostic Stade avancé Tamoxifène Toxicité Traitement associé Interféron alpha 2b Cytokine Tumeur maligne
- Keyword (en)
- Alkylating agent Antineoplastic agent Antihormone Antiestrogen Drug combination Chemotherapy Complication Non steroid compound Dacarbazine Treatment efficiency Phase III trial Comparative study Human Immunotherapy Alpha interferon Melanoma Prognosis Advanced stage Tamoxifene Toxicity Combined treatment Cytokine Malignant tumor
- Keyword (es)
- Agente alquilante Anticanceroso Antihormona Antiestrógeno Asociación medicamentosa Quimioterapia Complicación Compuesto no esteroide Dacarbazina Eficacia tratamiento Ensayo clínico fase III Estudio comparativo Hombre Inmunoterapia Interferón alfa Melanoma Pronóstico Estadio avanzado Tamoxifeno Toxicidad Tratamiento asociado Citoquina Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R04 Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 2217177
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.1998.16.5.1743 
https://dx.doi.org/10.1200/JCO.1998.16.5.1743
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FALKSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:10:\"IBRAHIM, J\";i:1;s:14:\"KIRKWOOD, J. M\";i:2;s:12:\"CRATES, A. S\";i:3;s:12:\"ATKINS, M. B\";i:4;s:10:\"BLUM, R. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FALKSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:10:\"IBRAHIM, J\";i:1;s:14:\"KIRKWOOD, J. M\";i:2;s:12:\"CRATES, A. S\";i:3;s:12:\"ATKINS, M. B\";i:4;s:10:\"BLUM, R. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FALKSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:10:\"IBRAHIM, J\";i:1;s:14:\"KIRKWOOD, J. M\";i:2;s:12:\"CRATES, A. S\";i:3;s:12:\"ATKINS, M. B\";i:4;s:10:\"BLUM, R. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FALKSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:10:\"IBRAHIM, J\";i:1;s:14:\"KIRKWOOD, J. M\";i:2;s:12:\"CRATES, A. S\";i:3;s:12:\"ATKINS, M. B\";i:4;s:10:\"BLUM, R. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1200\/JCO.1998.16.5.1743\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1743\";s:8:\"\u0000*\u0000epage\";s:4:\"1751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FALKSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:10:\"IBRAHIM, J\";i:1;s:14:\"KIRKWOOD, J. M\";i:2;s:12:\"CRATES, A. S\";i:3;s:12:\"ATKINS, M. B\";i:4;s:10:\"BLUM, R. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:253:\"Phase III trial of dacarbazine versus dacarbazine with interferon \u03b1-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \u03b1-2b and tamoxifen in patients with metastatic malignant melanoma : An eastern cooperative oncology group study\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
